Press Releases
* Please note that the news release contains the content at the time of the announcement and may differ from the latest information.
Real Tech Fund Aims to Establish Cyborg Technology Using EMG Analysis Technology
Invested in "Meltin MMI Co., Ltd."
Euglena Investment Co., Ltd.
Euglena Investment Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative: Akihiko Nagata) is a new investment destination for the venture capital fund "Real Tech Fund", which integrates the human body and machines using myoelectric analysis technology. We are pleased to announce that we have invested in Meltin MMI Co., Ltd. (hereinafter referred to as Meltin), which aims to establish cyborg technology.
When a person moves a muscle, he / she sends an electric signal called myoelectricity. With conventional technology, it was difficult to read complex patterns of myoelectricity only by acquiring the presence or absence of myoelectricity generation, but with Meltin's original analysis technology using artificial intelligence, human movement intentions can be detailed. It can also be read.
At Meltin, by transmitting the myoelectric information obtained by the device using this myoelectric analysis technology to a machine that requires complicated operations such as an artificial hand, the machine realizes detailed operations according to human intentions. I will. In addition, by combining wearable devices, it is possible to operate without touching familiar electronic devices such as personal computers and smartphones. In addition, just by attaching an EMG analyzer to your hand, you will be able to grasp the health condition such as mental illness and stress condition from the EMG information of the heart.
This time, the Real Tech Fund will invest in Meltin and provide management support. In response, Meltin developed a myoelectric analyzer and utilized the myoelectric analyzer to jointly develop and put into practical use machines and wearable devices that can be operated with myoelectric information. I aim to go.
The details are as follows.
About investment in Meltin
■ About Meltin and support
| Date of establishment | : July 19, 2013 |
| Location | : 3-3-10 Shibuya, Shibuya-ku, Tokyo |
| Representative | : Representative Director Sumio Ito |
| Capital | : 48.79 million yen |
| Description of Business | : Development of EMG analyzer and commercialization using EMG analyzer |
| HP | : Http://meltin.jp/ |
| support | : Hands-on management support (commercialization support, fund procurement support, etc.) |
| Investment date | : January 2016 |
■ About Real Tech Fund (HP: www.euglena-investment.jp)
Our 100% subsidiary of Euglena Investment, SMBC Nikko Securities, Ribanesu "Limited Liability Company was founded three companies Euglena in venture capital funds that SMBC Nikko Ribanesu capital" to management and operation, the investment development of the real tech venture as the main purpose is. With a total of 17 participating companies and a fund size of 5.5 billion yen (increasing), it is one of the largest real tech-specialized funds in Japan. We are investing in and nurturing real-tech ventures together with each operating company that is an investor.
Investors: Euglena Investment Co., Ltd., Revanes Co., Ltd., SMBC Nikko Securities Co., Ltd., Nippon Tobacco Industry Co., Ltd., Mitsui Real Estate Co., Ltd., Yoshinoya Holdings Co., Ltd., Rohto Pharmaceutical Co., Ltd., Kanetsu Co., Ltd., Dentsu Co., Ltd., Tokyo Century Lease Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Aizawa Securities Co., Ltd., Shimizu Construction Co., Ltd., Sumitomo Mitsui Banking Corporation, ANA Holdings Co., Ltd., THK Co., Ltd., Toyo Aluminum Co., Ltd. (17 companies in total)
-Contact for inquiries from the press-
Euglena Co., Ltd. Public Relations and IR Division